Anti-HEV antibody prevalence in three distinct regions of Turkey and its relationship with age, gender, education and abortions


Olcay D., Eyigün C. P., Özgüven Ş. V., AVCI İ. Y., Beşirbellioǧlu A. B., TOSUN S., ...Daha Fazla

Turkish Journal of Medical Sciences, cilt.33, sa.1, ss.33-38, 2003 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 1
  • Basım Tarihi: 2003
  • Dergi Adı: Turkish Journal of Medical Sciences
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.33-38
  • Anahtar Kelimeler: Age, Anti-HEV antibody, Education and abortion, Epidemiology, Gender
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Hepatitis E virus (HEV) causes epidemics in developing countries such as India, Burma, Indonesia, Chad and China, but it causes sporadic cases in developed countries such as the U.S.A., Canada and the U.K. Turkey represents a bridge between HEV endemic and non-endemic areas, and HEV may cause epidemics in Turkey. In this study, the prevalence of HEV in three distinct regions of Turkey and its relationship with age, gender, education and abortions was investigated. Nine hundred ten randomly selected cases from three cities in three geographic regions of Turkey (Manisa from the Aegean region, Elmadaǧ/Ankara from Central Anatolia and Diyarbakir from Southeastern Anatolia) were enrolled in the study. After informed consent was obtained, the subjects completed a detailed questionnaire including questions about age, sex, education, and the number of pregnancies, abortions, stillbirths and live babies, and if there was a history of abortion from icteric pregnancy. We researched anti-HEV antibodies in the serum samples of subjects using ELISA. The overall anti- HEV antibody seroprevalence rate was 6.3% (57/910). It was 2.7% in Elmadaǧ/Ankara, 3.8% in Manisa and 11.7% in Diyarbakir. There was a significant difference between Diyarbakir and the other two regions (p < 0.0001). No significant difference was observed between the other parameters. In conclusion, the overall anti-HEV antibody seroprevalence rate was 6.3% and these rates increased with age.